Chu, M. P., Lieffers, J., Ghosh, S., Belch, A., Chua, N. S., Fontaine, A., Sangha, R., Turner, R. A., Baracos, V. E., and Sawyer, M. B. (2017) Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy. Journal of Cachexia, Sarcopenia and Muscle, 8: 298--304. doi: [10.1002/jcsm.12161](10.1002/jcsm.12161).

Introduction {#jcsm12161-sec-0005}
============

Skeletal muscle (radio)density (SMD) is reported as the mean radiation attenuation in Hounsfield Units (HU) on computed tomography (CT) imaging. Although SMD is measured within the range of −29 to 150 HU, most of the tissue area typically falls between 10 and 40 HU.[1](#jcsm12161-bib-0001){ref-type="ref"} SMD can vary greatly, and muscle with lower SMD has increased fat production or infiltration.[2](#jcsm12161-bib-0002){ref-type="ref"} In diabetes, inflammation is a proposed mechanism behind accumulation of excess intermuscular adipose tissue.[3](#jcsm12161-bib-0003){ref-type="ref"} Ectopic fatty infiltration of muscle may also be a phenomenon that contributes to muscle mass loss (sarcopenia).[4](#jcsm12161-bib-0004){ref-type="ref"} Clinically, sarcopenia and cachexia are related in cancer patients, both of which have been shown to be poor prognostic indicators.[5](#jcsm12161-bib-0005){ref-type="ref"} Low SMD, though, appears to be more prognostic than sarcopenia in both solid and haematologic cancers.[6](#jcsm12161-bib-0006){ref-type="ref"}, [7](#jcsm12161-bib-0007){ref-type="ref"}, [8](#jcsm12161-bib-0008){ref-type="ref"} It was previously observed that SMD was prognostic of survival in follicular lymphoma, an indolent form of non‐Hodgkin lymphoma. SMD has not yet been evaluated in the commonest form of aggressive non‐Hodgkin lymphoma, diffuse large B‐cell lymphoma (DLBCL). Because weight loss is described to be prognostic of survival in DLBCL,[9](#jcsm12161-bib-0009){ref-type="ref"} we hypothesized that this disease may be characterized by reduced SMD with likely prognostic significance.

After the advent of rituximab, a monoclonal antibody targeting CD20,[10](#jcsm12161-bib-0010){ref-type="ref"}, [11](#jcsm12161-bib-0011){ref-type="ref"} weight loss is less viewed as an important prognostic factor in DLBCL. Rather, older age is associated with poor prognosis in DLBCL based on the Revised International Prognostic Index (R‐IPI).[12](#jcsm12161-bib-0012){ref-type="ref"} Lanic *et al.*.[13](#jcsm12161-bib-0013){ref-type="ref"} have recently reviewed elderly patients with DLBCL to examine what aspects of that population may relate to poorer survival. Sarcopenia appeared to be a defining feature predictive of not only higher R‐IPI scores but also poorer overall survival (OS). However, Lanic *et al.* used a cut‐off of ≥70 years of age to define their elderly population whereas the R‐IPI uses an age of 60 years---highlighting that age cut‐offs can be difficult to define. Conceptually, the poor prognosis associated with sarcopenia should not be limited by age.[1](#jcsm12161-bib-0001){ref-type="ref"} Like SMD, sarcopenia in a wider DLBCL population has not been investigated.

Differences in muscle mass may also play a factor in DLBCL, sex‐specific outcomes. Males were identified as a DLBCL subgroup in the RICOVER60 study that did not have as large of an improvement in both progression free survival (PFS) and OS compared with females.[14](#jcsm12161-bib-0014){ref-type="ref"} In evaluating rituximab\'s pharmacokinetics, it was thought that males\' higher weight (and by extension, muscle mass) increased rituximab\'s clearance thereby correlating with its decreased efficacy. Subsequent retrospective data confirmed a survival advantage favouring females.[15](#jcsm12161-bib-0015){ref-type="ref"} It appears contradictory that lower muscle mass in females compared with males would improve rituximab\'s ability to linger in circulation and therefore lead to a better prognosis while at the same time lower muscle mass is an indicator of poor prognosis in elderly DLBCL patients. A more unifying explanation would be that prognosis is more related to SMD than to age and sex. SMD does not differ between sexes as does skeletal muscle mass.[1](#jcsm12161-bib-0001){ref-type="ref"} This study explored whether underlying sex and age outcome differences in DLBCL were related to SMD and sarcopenia.

Materials and methods {#jcsm12161-sec-0006}
=====================

Patients {#jcsm12161-sec-0007}
--------

Following institutional ethics review approval; DLBCL patients treated at a centralized, single institution of Northern Alberta (catchment population of \>1.8 million) from 2004 to 2009 were reviewed. Patient demographics including age, stage, R‐IPI score at diagnosis, sex, height, weight, and performance status were collected. The chemotherapy regimen they received, number of cycles received, and best response to first‐line therapy were then documented. PFS and OS were collected as primary endpoints. Objective response rates (ORR) to chemoimmunotherapy was the secondary endpoint.

Body composition analysis {#jcsm12161-sec-0008}
-------------------------

Height and weight at the first cycle of treatment were documented. Body composition was assessed using each patient\'s pre‐treatment, staging CT scans. To be included in review, CT scans must have been within 30 days prior to beginning therapy. To ensure image quality, CT scanner calibration was performed daily at start up with using air in the CT scanner gantry, then dynamically during scanning for individual patients using air as a negative control. Therefore, although CT tube current may fluctuate between patients, variability is minimal yielding the following CT parameters for each patient: contrast enhanced or unenhanced, 5 mm slice thickness, 120 kVp, and 290 mA. Two adjacent images at the L3 vertebral body level were used to measure total muscle surface area (cm^2^) and averaged. This vertebral landmark is chosen based on its linear correlation to total body lean body mass.[16](#jcsm12161-bib-0016){ref-type="ref"}, [17](#jcsm12161-bib-0017){ref-type="ref"} Muscles were quantified within a range of −29 to 150 HU using Slice‐O‐Matic software (version 5.0, TomoVision, Magog, Quebec, Canada). Measurements were normalized to patient\'s height in metres squared and expressed as skeletal muscle index (reported as cm^2^/m^2^).

SMD was quantified as mean muscle radiation attenuation (HU) of the muscle cross‐sectional area across the L3 vertebral body level was assessed between −29 and +150 HU.[18](#jcsm12161-bib-0018){ref-type="ref"}

Statistical analysis {#jcsm12161-sec-0009}
--------------------

The general principle of SMD and skeletal muscle index analysis is that there is a threshold value (cut point) within these continuous variables, below which there is a significant increase in risk of mortality. Such statistically defined cut points have been described in large populations of patients with solid tumours, but mortality‐related cut point values for haematological malignancies are lacking.[1](#jcsm12161-bib-0001){ref-type="ref"} For that reason, this exploratory analysis in DLBCL adopted two approaches: (i) testing SMD and skeletal muscle index cut points defined by various sources in the literature including Lanic *et al.*,[13](#jcsm12161-bib-0013){ref-type="ref"} Prado *et al.*,[19](#jcsm12161-bib-0019){ref-type="ref"} and Martin *et al.*;[1](#jcsm12161-bib-0001){ref-type="ref"} and (ii) evaluation of cut point values within our population by a cut‐point analysis using minimal *p*‐value approach.[20](#jcsm12161-bib-0020){ref-type="ref"} The continuous variable was divided into different cut‐points and the cut‐point that provides maximum chi‐square or provides minimum *p*‐value is chosen to be the point for dichotomizing the continuous variable.

Kaplan--Meier methods were used to compare PFS and OS between these groups of high vs. low SMD and skeletal muscle index. Survival was then compared by log‐rank test and multivariate Cox proportional hazards modelling using sex and R‐IPI score as covariates. ORR was compared by chi‐squared analysis employing a two‐sided *p*‐value. Statistical analysis was done using Statistical Analysis System (SAS, version 9.3 from SAS Institute Incorporated, Cary, North Carolina).

Results {#jcsm12161-sec-0010}
=======

Patients {#jcsm12161-sec-0011}
--------

Between 2004 and 2009, 232 patients with DLBCL were treated with chemoimmunotherapy. Of those, 224 were eligible for review, with eight excluded because of either ineligible pre‐treatment CT images (6) or no images available for review (2). There were 124 males and 100 females. Median age at diagnosis was 62, with a range of 21 to 88 years. While median stage at diagnosis was III, the majority of patients presented with stage IV disease (46%). Median R‐IPI score was 3 with all patients receiving R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patient characteristics are summarized in Table [1](#jcsm12161-tbl-0001){ref-type="table-wrap"}. For the entire cohort, 5 year PFS and OS were 69 and 72%, respectively.

###### 

Patients demographics and response to chemoimmunotherapy divided by skeletal muscle density (SMD) and low (≤25 kg/m^2^) or high (\>25 kg/m^2^) body mass index (BMI)

  Demographic                                      All (224)     Low SMD (116)   High SMD (108)   Low vs. High SMD *p*‐value              
  ------------------------------------------------ ------------- --------------- ---------------- ---------------------------- ---------- ----------
  Age at diagnosis, median (years)                 62 (21--88)   65              69               49                           56         \<0.0001
  Sex, \#                                                                                                                                 0.02
  Male                                             125 (56%)     19 (44%)        34 (47%)         25 (66%)                     47 (59%)   
  Female                                           99 (44%)      24 (56%)        39 (53%)         13 (34%)                     23 (41%)   
  Body weight, median (kg)                         75.7          61.7            83.3             61.8                         78.8       \<0.0001
  Body mass index, median (kg/m^2^)                26.8          22.5            30.1             22.2                         28.0       \<0.0001
  Stage, \#                                                                                                                               0.24
  I                                                50 (22%)      8 (19%)         13 (18%)         6 (16%)                      23 (33%)   
  II                                               44 (20%)      5 (12%)         13 (18%)         12 (32%)                     14 (20%)   
  III                                              27 (12%)      4 (9%)          13 (18%)         3 (8%)                       7 (10%)    
  IV                                               103 (46%)     26 (60%)        34 (47%)         17 (45%)                     26 (33%)   
  R‐IPI, \#                                                                                                                               0.0001
  0                                                18 (8%)       0               2 (3%)           8 (21%)                      8 (11%)    
  1                                                44 (20%)      5 (12%)         12 (16%)         9 (24%)                      18 (26%)   
  2                                                48 (21%)      6 (14%)         14 (19%)         5 (13%)                      23 (33%)   
  3                                                58 (26%)      18 (42%)        21 (29%)         7 (18%)                      12 (17%)   
  4                                                40 (18%)      8 (19%)         15 (21%)         9 (24%)                      8 (11%)    
  5                                                16 (7%)       6 (14%)         9 (12%)          0                            1 (1%)     
  Chemoimmunotherapy cycles received, median       6             6               6                6                            6          
  Best response to chemoimmunotherapy, \#                                                                                                 0.04
  Complete response                                168 (75%)     30 (70%)        46 (63%)         31 (82%)                     61 (87%)   0.0007
  Partial response                                 41 (18%)      9 (21%)         21 (29%)         7 (18%)                      4 (6%)     
  Stable disease                                   2 (0.1%)      1 (2%)          0                0                            1 (1%)     
  Progressive disease                              13 (6%)       3 (7%)          6 (8%)           0                            4 (6%)     
  Required at least 1 cycle delayed, \#            90 (40%)      17 (40%)        30 (41%)         18 (47%)                     25 (36%)   0.78
  CT measures                                                                                                                             
  Median skeletal muscle area (cm^2^)              130.7         109.1           126.0            127.6                        157.6      \<0.0001
  Median skeletal muscle index (SMI, cm^2^/m^2^)   47.7          40.4            46.5             45.0                         54.3       \<0.0001
  SMD (HU)                                         34.1          32.9            25.0             45.5                         38.9       \<0.0001

Skeletal muscle density {#jcsm12161-sec-0012}
-----------------------

Median SMD for the entire group was 34.1 HU. Cut‐point analysis revealed a substantial difference in survival with SMD at 40 and 33 HU for non‐overweight and overweight patients, respectively. These definitions are nearly identical to the 41 and 33 HU for non‐overweight and overweight solid tumour patients, respectively.[1](#jcsm12161-bib-0001){ref-type="ref"} Using one definition over the other changed the designation of only one patient between high or low SMD and did not meaningfully change outcomes---therefore, previously validated solid tumour SMD definitions were used for survival comparisons. Median PFS was not reached in either high or low SMD group, but patients with low SMD had profoundly poorer PFS (*Figure* [1](#jcsm12161-fig-0001){ref-type="fig"}, HR 2.28, 1.33--3.76, *p* = 0.002). At 5 years, PFS was 81 vs. 60% in high and low SMD patients, respectively (*p* = 0.001). Similarly, median OS in the high SMD group was not reached vs. 103.6 months in the low group (*Figure* [2](#jcsm12161-fig-0002){ref-type="fig"}, HR 3.50, 1.99--6.16, *p* \< 0.0001). Five‐year OS was 86 vs. 58% (*p* \< 0.0001) in high and low SMD patients, respectively.

![Kaplan--Meier (KM) analysis of progression free survival based on skeletal muscle density (SMD).](JCSM-8-298-g001){#jcsm12161-fig-0001}

![KM analysis of overall survival by SMD.](JCSM-8-298-g002){#jcsm12161-fig-0002}

After adjusting for R‐IPI scores and sex in multivariate Cox proportional hazards regression (Table [2](#jcsm12161-tbl-0002){ref-type="table-wrap"}), low SMD retained prognostic significance in OS (HR 2.52, 1.40--4.54, *p* = 0.002, *R* ^2^ = 0.133). Its prognostic ability in PFS trended toward significance (HR 1.56, 0.90--2.71, *p* = 0.11)

###### 

Univariate and multivariate Cox proportional hazards modelling by skeletal muscle density (SMD), Revised International Prognostic Index (R‐IPI), and sex

                     Univariate analysis   Multivariate analysis                                                    
  ------------------ --------------------- ----------------------- ------------- ------ ------------- ------------- ------
  PFS                R‐IPI score 1--2      1.58                    0.36--6.92    0.54   1.29          0.29--5.75    0.74
  R‐IPI score 3--5   5.39                  1.31--22.17             0.02          4.20   0.98--17.88   0.05          
  Sex, male          0.87                  0.54--1.42              0.59          0.98   0.60--1.61    0.95          
  Low SMD            2.28                  1.35--3.83              0.002         1.56   0.90--2.71    0.11          
  OS                 R‐IPI score 1--2      3.05                    0.40--23.08   0.28   2.18          0.28--16.74   0.45
  R‐IPI score 3--5   10.13                 1.40--73.31             0.02          6.26   0.84--46.4    0.07          
  Sex, male          1.00                  0.62--1.62              1             1.23   0.76--2.02    0.40          
  Low SMD            3.45                  1.96--6.07              \<0.0001      2.52   1.40--4.54    0.002         

Skeletal muscle index {#jcsm12161-sec-0013}
---------------------

There was no significant difference in PFS comparing patients above and below established skeletal muscle index levels set out by either Prado, Martin or Lanic *et al.* (*p* = 0.19, 0.17, and 0.23, respectively). OS comparison was also not significant by these three definitions. By cut‐point analysis, the most significant difference was identified at cross‐sectional muscle area of 53.3 cm^2^/m^2^ for males and 40.2 cm^2^/m^2^ for females. Using these levels, patients with low skeletal muscle index had a trend toward improved PFS (HR 0.65, 0.41--1.05, *p* = 0.08). This definition of skeletal muscle index was not prognostic of OS (HR 0.77, 0.48--1.25, *p* = 0.30).

Given previous evidence of poorer survival in sarcopenic elderly patients, a subgroup analysis of elderly in this cohort (as defined by Lanic *et al.* to be patients \> 70 years of age) was done using Lanic *et al.* parameters and our cut‐points. Having skeletal muscle indices below Lanic *et al.*\'s and our own cut‐points yielded PFS HRs of 0.24 (0.01--0.61, *p* = 0.003) and 0.19 (0.07--0.50, *p* = 0.0007), respectively. Similar to PFS, OS for patients with low skeletal muscle indices had HRs of 0.45 (0.21--0.99, *p* = 0.05) and 0.38 (0.17--0.82, *p* = 0.01), respectively.

Response to chemoimmunotherapy {#jcsm12161-sec-0014}
------------------------------

In secondary endpoint analysis, ORR were very similar between high and low SMD groups (95.4 vs. 91.4%, *p* = 0.17). However, there was a strong association between high SMD patients and attaining a complete response (85 vs. 66%, *p* = 0.0007, Table [1](#jcsm12161-tbl-0001){ref-type="table-wrap"}). There was no difference in ORR based on skeletal muscle index.

Discussion {#jcsm12161-sec-0015}
==========

Values for skeletal muscle mass as estimated by skeletal muscle index have been used to describe sex and age‐based outcomes in DLBCL. Sarcopenia, the loss of skeletal muscle, has been associated with poorer elderly patient outcomes.[13](#jcsm12161-bib-0013){ref-type="ref"} Conversely, higher muscle mass is suggested as a reason for increased rituximab clearance and poorer outcomes in males.[10](#jcsm12161-bib-0010){ref-type="ref"}, [15](#jcsm12161-bib-0015){ref-type="ref"} In this study, low SMD appeared to be more prognostic of poor patient survival than skeletal muscle index. Low SMD is also similarly more prognostic than skeletal muscle index in melanoma, renal cell cancer, and follicular lymphoma.[6](#jcsm12161-bib-0006){ref-type="ref"}, [7](#jcsm12161-bib-0007){ref-type="ref"}, [8](#jcsm12161-bib-0008){ref-type="ref"} It is important to note that cut‐point analysis in our study independently established the same SMD parameters defined in solid organ malignancies---providing early validation of its continued use of these cut points in DLBCL.[1](#jcsm12161-bib-0001){ref-type="ref"} While additional software was used to retrospectively determine SMD levels in patients\' pre‐treatment CT scans, mean muscle radiation attenuation is data routinely measured by CT scanners. As such, SMD is easily obtainable data that does not require any additional assays or equipment to complement R‐IPI in stratifying DLBCL patient prognosis.

However, the fact that SMD was strongly associated with complete response to rituximab‐based therapy raises questions as to whether it is simply prognostic or also a predictor of treatment response. Perhaps its ability to predict complete response is therefore also related to its PFS prognostic ability. Although multivariate PFS analysis did not quite meet statistical significance, it should be noted that the original R‐IPI was established based on its ability to predict OS.[12](#jcsm12161-bib-0012){ref-type="ref"} Our findings were meant to be exploratory and, therefore, in a retrospective model, cannot determine the answer to the question of whether SMD is a predictive or prognostic marker. Along those lines, further investigation as to whether low SMD can be reversed following chemoimmunotherapy (and whether this change then impacts outcomes) is currently being investigated.

A unifying theory explaining how ectopic fat infiltration of muscle develops is elusive and likely suggests that multiple factors are at play. Although early thinking suggested this phenomenon was part of normal ageing, larger studies now suggest that intermuscular fat development is more of a product of illness and/or inactivity.[21](#jcsm12161-bib-0021){ref-type="ref"}, [22](#jcsm12161-bib-0022){ref-type="ref"} The latter explanation may suggest that low SMD in this study may be a form of objective and quantitative performance status measurement. However, performance status is taken into account in R‐IPI scoring and so, for low SMD to be independently prognostic in a model that already includes performance status would seem surprising. Rather, based on differences in complete response to rituximab‐based therapy, low SMD may suggest a more substantial change in overall patient physiology as a result of DLBCL or cancer as a whole. Ectopic fatty infiltration of skeletal muscles has been observed in other diseases such as severe type 2 diabetes, where its presence is associated with particularly poor disease control and prognosis. This altered muscle physiology in diabetes is associated with elevated serum inflammatory markers such as tumour necrosis alpha, C‐reactive protein, and interleukin‐6.[3](#jcsm12161-bib-0003){ref-type="ref"} Speculating in this way, DLBCL patients with low SMD may have either more severe disease or a specific, pro‐inflammatory, host response that leads to changes in muscle physiology manifesting in both intermuscular fat deposition and poorer clinical outcomes. DLBCL itself is a heterogeneous disease made up of multiple subtypes: where non‐germinal centre disease is thought to behave more poorly than germinal centre type even with rituximab‐containing therapy.[23](#jcsm12161-bib-0023){ref-type="ref"}, [24](#jcsm12161-bib-0024){ref-type="ref"} Given that low SMD is also prognostic of follicular lymphoma outcomes,[8](#jcsm12161-bib-0008){ref-type="ref"} SMD is unlikely to be strictly related to non‐germinal centre DLBCL. Subsequent work is needed to properly characterize the pathways involved in fatty infiltration of muscle and how it may relate to lymphoma.

Lanic *et al.* sought to extrapolate findings in solid organ malignancies where sarcopenia is associated with poorer outcomes and apply it to elderly DLBCL patients.[13](#jcsm12161-bib-0013){ref-type="ref"} Their review found sarcopenia was more prevalent amongst patients ≥ 70 years old and predicted poorer survival. While sarcopenia is more prevalent in the elderly, the concept of poorer outcomes in sarcopenic patients should apply to the whole DLBCL population. However, our findings suggest that sarcopenic DLBCL patients in fact have a trend toward better PFS. As part of a pre‐planned subgroup analysis similar to the Lanic *et al.* group, elderly patients (age \> 70 years) displayed an even more pronounced improvement in both PFS and OS. These findings would seem to not only contradict Lanic *et al.*\'s findings, but it also speaks against findings in other solid organ tumours.[1](#jcsm12161-bib-0001){ref-type="ref"}, [19](#jcsm12161-bib-0019){ref-type="ref"}, [25](#jcsm12161-bib-0025){ref-type="ref"} An explanation as to why this stands in opposition to prior literature regarding sarcopenia is not currently available. One possible explanation might relate to the unusually high proportion of females in the study of Lanic *et al.*.[9](#jcsm12161-bib-0009){ref-type="ref"} Pfreundschuh *et al.* [11](#jcsm12161-bib-0011){ref-type="ref"} theorized that males had an increased clearance because of their higher average weight leading to less rituximab exposure and consequently poorer outcomes.[14](#jcsm12161-bib-0014){ref-type="ref"} It is possible that this concept may apply to this sarcopenic population. As a result of having less skeletal muscle mass, sarcopenic patients may have lower volumes of distribution and are therefore being exposed to relatively higher concentrations of rituximab as compared with similarly sized patients who have normal skeletal muscle mass. Therefore, these patients may have improved outcomes as a consequence of higher rituximab plasma concentrations. Prospective studies are needed to confirm this speculation.

Limitations of this study include inherent bias introduced by a retrospective analysis. Serum inflammatory markers were also not uniformly available across this sample because of its retrospective nature as well. During time points studied, eight cycles of R‐CHOP chemotherapy had not yet been thought to be equivalent to six cycles and was therefore still utilized. While R‐IPI accounts for Eastern Cooperative Oncology Group performance status, more objective performance measures such as walking speed or hand grip were clearly not evaluable retrospectively. Consequently, future directions include incorporating SMD assessment with R‐IPI prospectively. Given a possible link between SMD and inflammation, studies are underway to determine if there is an association between low SMD and serial measurements of inflammatory serum markers. A separate assessment of whether SMD changes with chemoimmunotherapy is also underway.
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